The Bacillus Calmette-Guérin accine may alter immune activity around the brain and change levels of a protein closely associated with Alzheimer’s disease in older adults without evidence of the condition.
FDA has approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation.
The Healthcare Advisory Committee will develop actionable policy solutions, advance accountability for safety and more.
The new federal advisory body, the Healthcare Advisory Committee, will provide advice on modernizing healthcare in the U.S.
FDA-approved Kresladi (marnetegragene autotemcel) is the first gene therapy treating leukocyte adhesion deficiency type I (LADI).
A UTHealth study found adults 65 and older had a lower risk of developing Alzheimer’s disease after receiving a high-dose flu vaccine.
CMS has launched HealthTech tools to streamline care and digitize the patient experience.
A new CMS Comprehensive Care for Joint Replacement (CJR) Model proposal could lower costs nationwide for Medicare beneficiaries undergoing knee, hip and ankle replacements.
The Statens Serum Institut in Copenhagen found that flu vaccines may protect against heart attack and stroke, even if the flu is still developed after vaccination.
Avlayah (tividenofusp alfa-eknm) has been FDA-approved to treat some individuals with Hunter Syndrome (Mucopolysaccharidosis type II or MPS II).
The novel opioid DFNZ shows potential for pain and opioid use disorder without causing depressed breathing.
Immune-mediated inflammatory disease (IMID) patients have been found to have a high risk of developing cancer, but that risk declines as inflammation decreases.